Dyne Therapeutics to present additional Phase 1/2 trial data
Dyne Therapeutics plans to present additional one-year Phase 1/2 ACHIEVE trial data for z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1) at upcoming medical meetings.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.